Issoire, October 26, 2022, 7:30 a.m. CEST – BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacture of medical devices and injectable drug delivery systems, announces the signing of a partnership agreement with Novo Nordisk for the marketing of Mallya, primarily in Japan.
This new agreement reinforces the partnership between Novo Nordisk and BIOCORP focused on the development of the Mallya product announced in September 2021. While this first development agreement only covered brands in the field of insulin, another therapeutic area in which Novo Nordisk is present was included earlier this year.
Mallya (non-medical device in Japan) is a smart sensor that attaches directly to Novo Nordisk’s FlexTouch® insulin pens. Mallya will enable diabetic patients using FlexTouch® pens to automatically collect and record data related to their daily insulin injections, such as number of insulin units, date and time. Thanks to a mobile application linked to Mallya, patients will be able to trace the history of their injections and monitor their treatment in real time. Mallya is compatible with all Novo Nordisk FlexTouch® insulin pens. Based on this agreement, Novo Nordisk will market Mallya in Japan from the first half of 2023.